
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Enfis, a Wales-based company, is working to bring to market a laser designed to cure acne and has been given the go-ahead to start clinical trials.